파이프라인_Biocytogen Pharmaceuticals (Beijing) Co., Ltd._Biocytogen, drug development, antibody discovery

바이오사이토젠은 환자의 수요를 만족시키는 혁신적인 항체 신약 개발을 위하여, 항암, 자가면역질환, 대사질환, 감염질환 등의 다양한 질병 영역에서 독자적이며 혁신적인 신약개발 능력을 활용하여 단일클론항체, 이중특이성항체, ADC 등을 포함한 십여개의 연구개발중인 파이프라인을 보유하고 있습니다. 강력한 임상개발팀과 풍부한 임상자원을 바탕으로, 잠재력있는 파이프라인의 개발을 가속화하여 신약의 임상 개발 과정을 앞당기고 있습니다.

Therapeutic Area

Product

Target(s)

Partner

Molecular Format

Indication(s)

Status

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Oncology

YH003

CD40

mAb

Solid tumors

YH001

CTLA-4

TRACON

mAb

Solid tumors

YH002

OX40

mAb

Solid tumors

YH004

4-1BB

mAb

Solid tumor + Hematological malignancy

YH005-ADC

Claudin18.2- ADC

Remegen

ADC

YH008

PD-1 x CD40

Chipscreen NewWay

BsAb

Solid tumors

YH012

HER2 x TROP2

BsADC

Solid tumors

YH013

EGFR x MET

BsADC

Solid tumors

YH016

Undisclosed

Oncology

BCG003

TNFR2

Dragonboatbio

mAb

Solid tumors

BCG008

SIGLEC15

Undisclosed

mAb

Solid tumors

BCG011

TROP2 x EGFR

Undisclosed

BsADC

Oncology

BCG012

HER3 x MUC1

Undisclosed

BsADC

Oncology

BCG001

B7-H3

Mabworks

mAb

Solid tumors

BCG005

CCR8

LiberoThera

mAb

Solid tumors

BCG007

AMHR2

Undisclosed

mAb

Solid tumors

BCG002

CD24

mAb

Solid tumors

BCG006

WT1

Undisclosed

TCRm

Oncology

BCG010

NKG2A

Undisclosed

mAb

Oncology

BCG013

5T4 x MET

Undisclosed

BsADC

Oncology

Inflammation and Autoimmunity

YH015

CD40 inhibitor

mAb

Autoimmunity

YH017

Undisclosed

Autoimmunity

Infectious Diseases

BCG004

Rabies virus

Undisclosed

mAb

Infectious Diseases

Rare Diseases

BCG009

Undisclosed

mAb

Rare diseases

Oncology

YH003

Target：

CD40

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH001

Target：

CTLA-4

Partner：

TRACON

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH002

Target：

OX40

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH004

Target：

4-1BB

Partner：

Molecular Format：

mAb

Indication：

Solid tumor + Hematological malignancy

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH005-ADC

Target：

Claudin18.2- ADC

Partner：

Remegen

Molecular Format：

ADC

Indication：

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH008

Target：

PD-1 x CD40

Partner：

Chipscreen NewWay

Molecular Format：

BsAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH012

Target：

HER2 x TROP2

Partner：

Molecular Format：

BsADC

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH013

Target：

EGFR x MET

Partner：

Molecular Format：

BsADC

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH016

Target：

Undisclosed

Partner：

Molecular Format：

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG003

Target：

TNFR2

Partner：

Dragonboatbio

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG008

Target：

SIGLEC15

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG011

Target：

TROP2 x EGFR

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG012

Target：

HER3 x MUC1

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG001

Target：

B7-H3

Partner：

Mabworks

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG005

Target：

CCR8

Partner：

LiberoThera

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG007

Target：

AMHR2

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG002

Target：

CD24

Partner：

Molecular Format：

mAb

Indication：

Solid tumors

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG006

Target：

WT1

Partner：

Undisclosed

Molecular Format：

TCRm

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG010

Target：

NKG2A

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

BCG013

Target：

5T4 x MET

Partner：

Undisclosed

Molecular Format：

BsADC

Indication：

Oncology

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Inflammation and Autoimmunity

YH015

Target：

CD40 inhibitor

Partner：

Molecular Format：

mAb

Indication：

Autoimmunity

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

YH017

Target：

Undisclosed

Partner：

Molecular Format：

Indication：

Autoimmunity

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Infectious Diseases

BCG004

Target：

Rabies virus

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Infectious Diseases

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

Rare Diseases

BCG009

Target：

Undisclosed

Partner：

Undisclosed

Molecular Format：

mAb

Indication：

Rare diseases

Discovery

Pre-clinical

IND

Phase l

Phase ll

Phase lll

BLA

바이오사이토젠은 이미 전 세계의 여러 제약회사들과 완전 인간 항체 생산 마우스 플랫폼의 사용 계약과 항체신약 개발의 파트너쉽을 체결하였습니다. 파트너쉽에 대해 더 알아보시려면 아래를 클릭해주세요.

파이프라인과 관련된 합작 문의 : bd@eucure.com

합작연구개발

naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html